Trials / Active Not Recruiting
Active Not RecruitingNCT07165015
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3537031 | Administered SC |
Timeline
- Start date
- 2025-09-18
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2025-09-10
- Last updated
- 2026-03-19
Locations
4 sites across 2 countries: United States, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07165015. Inclusion in this directory is not an endorsement.